Philip Bonomi to Drug Resistance, Neoplasm
This is a "connection" page, showing publications Philip Bonomi has written about Drug Resistance, Neoplasm.
Connection Strength
0.691
-
Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. Cancer Discov. 2020 01; 10(1):40-53.
Score: 0.171
-
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer. Ann Oncol. 2018 08 01; 29(8):1701-1709.
Score: 0.157
-
The serum-based VeriStrat? test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients. BMC Cancer. 2018 03 20; 18(1):310.
Score: 0.153
-
Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer. Expert Rev Anticancer Ther. 2010 Oct; 10(10):1589-99.
Score: 0.091
-
Review of selected randomized trials in small cell lung cancer. Semin Oncol. 1998 Aug; 25(4 Suppl 9):70-8.
Score: 0.039
-
Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung. J Thorac Oncol. 2012 Oct; 7(10):1618-21.
Score: 0.026
-
A Phase II trial of Denileukin Diftitox in patients with previously treated advanced non-small cell lung cancer. Am J Clin Oncol. 2009 Jun; 32(3):269-73.
Score: 0.021
-
ZD0473 treatment in lung cancer: an overview of the clinical trial results. Eur J Cancer. 2002 Dec; 38 Suppl 8:S13-8.
Score: 0.013
-
Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial. J Clin Oncol. 2000 Jan; 18(1):131-5.
Score: 0.011
-
Regrowth resistance as a likely significant contributor to treatment failure in drug-sensitive neoplastic diseases. Cancer Invest. 1997; 15(4):358-68.
Score: 0.009